期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 178, 期 6, 页码 1373-1387出版社
WILEY
DOI: 10.1111/bph.15386
关键词
amyotrophic lateral sclerosis; cannabinoids; CB2 receptors; endocannabinoid signalling system; neurodegeneration; neuroprotection
资金
- MICIN Programa Nacional de Biomedicina [RTI2018-098885-B-100]
- CIBERNED, Instituto de Salud Carlos [CB06/05/0089]
- ELA-Madrid [B2017/BMD-3813]
- Emerald Health Pharmaceuticals
- GW Pharmaceuticals
Cannabinoids have therapeutic effects by targeting different elements of the endocannabinoid system, with potential as neuroprotective agents in ALS. The focus is on the activation of the CB2 receptor to limit glial reactivity, and there is a need for clinical trials to confirm the potential of cannabinoid-based medicines in ALS.
Cannabinoids form a singular group of plant-derived compounds, endogenous lipids and synthetic derivatives with multiple therapeutic effects exerted by targeting different elements of the endocannabinoid system. One of their therapeutic applications is the preservation of neuronal integrity exerted by attenuating the multiple neurotoxic events that kill neurons in neurodegenerative disorders. In this review, we will address the potential of cannabinoids as neuroprotective agents in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disorder characterized by muscle denervation, atrophy and paralysis, and progressive deterioration in upper and/or lower motor neurons. The emphasis will be paid on the cannabinoid type 2 (CB2) receptor, whose activation limits glial reactivity, but the potential of additional endocannabinoid-related targets will be also addressed. The evidence accumulated so far at the preclinical level supports the need to soon move towards the patients and initiate clinical trials to confirm the potential of cannabinoid-based medicines as disease modifiers in ALS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据